On Friday, March 4, 2022, the U.S. Food and Drug Administration approved nivolumab with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.
Read the FDA announcement.
Read Bristol Myers Squibb's announcement.
Posted 3/7/2022
